Amgen stock price hits 52-week high after Friday rally — what to watch into Monday
New York, Feb 7, 2026, 17:15 EST — Market’s done for the day.
- Amgen finished Friday’s session up roughly 4.5%, settling at $384.32.
- Starting April 1, CVS Caremark will pull Amgen’s Prolia off certain preferred drug lists, swapping in biosimilars instead.
- Next week, traders are eyeing key inflation figures and any fresh U.S. drug-pricing developments.
Amgen Inc ended Friday up 4.5% at $384.32, notching a fresh 52-week high as the stock extended its rally to a third straight session. 1
This move throws Amgen’s stock into the crosshairs of two competing currents: pressure from payers on fading blockbusters, and a spotlight on the company’s longer-term growth stories. CVS Health announced its…
